Truist Financial Corp Cytom X Therapeutics, Inc. Transaction History
Truist Financial Corp
- $71.8 Billion
- Q3 2025
A detailed history of Truist Financial Corp transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Truist Financial Corp holds 12,500 shares of CTMX stock, worth $44,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,500Holding current value
$44,000% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CTMX
# of Institutions
97Shares Held
122MCall Options Held
305KPut Options Held
121K-
Vr Adviser, LLC New York, NY14MShares$49.2 Million6.28% of portfolio
-
Tang Capital Management LLC San Diego, CA11.1MShares$39 Million1.5% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.95MShares$31.5 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.46MShares$29.8 Million0.69% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.08MShares$28.5 Million0.04% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $232M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...